Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Endocr Relat Cancer. 2020 Jan;27(1):1–9. doi: 10.1530/ERC-19-0370

Table 1.

PCa patient characteristics for those with PSA ≤ 10 that developed biochemical recurrence or those that remained recurrence-free 5 years following radical prostatectomy.

Variable All patients (N=181) Recurrence status at 5 years post-surgery
Non-Recurrence (N=98) Recurrence (N=83)
Age at surgery (Years)
 Mean (± SD) 59.98 (± 6.86) 59.24 (± 7.04) 60.86 (± 6.58)
Total Gleason
 5–6 60 (33.15) 50 (83.33) 10 (16.67)
 7 114 (62.98) 48 (42.11) 66 (57.89)
 8–9 7 (3.87) 0 (0) 7 (100)
Surgical margin
 No 139 (76.80) 89 (64.03) 50 (35.97)
 Yes 42 (23.20) 9 (21.43) 33 (78.57)
T stage
 T2 142 (78.45) 90 (63.38) 52 (36.62)
 T3 39 (21.55) 8 (20.51) 31 (79.49)
NCCN Risk Stratification
 Low 13 (7.18) 12 (92.31) 1 (7.69)
 Interm.-Favorable 97 (53.59) 42 (43.30) 55 (56.70)
 Interm.-Unfavorable 39 (21.55) 10 (25.64) 29 (74.36)
 High 7 (3.87) 1 (14.29) 6 (85.71)
 Very High 3 (1.66) 1 (33.33) 2 (66.66)
Pre-surgery PSA (ng/mL)
 Median (IQR) 5.00 (4.30 – 6.72) 4.64 (3.90 – 6.30) 5.60 (4.60 – 7.50)
sCD105 (ng/ml)
 Median (IQR) 5.54 (3.51 – 7.32) 5.71 (4.06 – 7.63) 5.2 (2.96 – 6.97)

Data for Non-Recurrence or Recurrence columns are presented as number of patients (row %), mean (± SD) or median (IQR, interquartile range) as appropriate. The data for All patients are presented as number of patients (column %), mean (± SD) or median (IQR, interquartile range) as appropriate.